Lilly Gives Investors A Glimpse At Post-2014 Balance Sheet
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly says R&D and SG&A spending will decline as a percent of sales post-2014, likely resulting in spending cuts, when the company expects to return to sales growth after cycling through important patent losses.